^
    2d
    Rescue of Suprasellar Metastasis of EGFR-mutant NSCLC by Daily Osimertinib Re-escalation With Filgrastim Support. (PubMed, In Vivo)
    This case suggests that dose reduction can weaken the effect of osimertinib on the CNS and that maintaining dose intensity using granulocyte colony-stimulating factor support is a viable and effective strategy for controlling CNS lesions in eloquent areas when local therapy is contraindicated.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Neupogen (filgrastim)
    3d
    Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma (clinicaltrials.gov)
    P2, N=174, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Jan 2028 --> Feb 2027
    Trial completion date
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • mesna • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    6d
    Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome (clinicaltrials.gov)
    P2/3, N=20, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Phase classification: P3 --> P2/3
    Phase classification
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Neupogen (filgrastim) • plerixafor
    8d
    Neupogen/MSCs conditioned media inhibit HEp-2 laryngeal cancer cells proliferation by down regulating miRNA 21expression and ROS production. (PubMed, Mol Biol Rep)
    Neupogen and MSCs-conditioned media are effective in suppressing the proliferation of Hep2 cells by targeting various components of the ROS-cytokine- STAT3-miRNA-21 signaling axis. Their combined therapy has shown potent anticancer effects, which are promising to be used in multi-targeted cancer treatment.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MIR21 (MicroRNA 21)
    |
    Neupogen (filgrastim)
    24d
    Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET (clinicaltrials.gov)
    P3, N=379, Completed, Children's Oncology Group | Active, not recruiting --> Completed | Trial completion date: Jun 2028 --> Mar 2026
    Trial completion • Trial completion date
    |
    cisplatin • carboplatin • cyclophosphamide • vincristine • Neupogen (filgrastim)
    25d
    PM1183-C-010-22: Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with Metastatic Leiomyosarcoma (2022-502975-45-00)
    P2/3, N=345, Active, not recruiting, Pharma Mar S.A. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    doxorubicin hydrochloride • dexamethasone • Zepzelca (lurbinectedin) • Neupogen (filgrastim) • ondansetron
    25d
    Gineco-ov133b: REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy. (2025-524232-20-00)
    P1/2, N=43, Not yet recruiting, Asso De Recherche Cancers Gynecologiques
    New P1/2 trial
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • ubamatamab (REGN4018) • Neupogen (filgrastim)
    27d
    Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas (clinicaltrials.gov)
    P1, N=20, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: Apr 2026 --> Dec 2025
    Enrollment open • Trial initiation date
    |
    doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    27d
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Apr 2026 --> Sep 2026
    Trial initiation date
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)
    1m
    Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, St. Jude Children's Research Hospital
    New P2 trial
    |
    cyclophosphamide • Campath (alemtuzumab) • sirolimus • hydroxyurea • thiotepa • Neupogen (filgrastim) • Orencia (abatacept)
    1m
    EA8192: Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (clinicaltrials.gov)
    P2/3, N=131, Recruiting, National Cancer Institute (NCI) | N=249 --> 131
    Enrollment change
    |
    MSI (Microsatellite instability) • CD4 (CD4 Molecule)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • doxorubicin hydrochloride • methotrexate • vinblastine • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • methotrexate IV
    1m
    Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=2, Terminated, Northwestern University | Active, not recruiting --> Terminated; Low accrual
    Trial termination
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    IDH1 R132
    |
    cytarabine • Tibsovo (ivosidenib) • idarubicin hydrochloride • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)